KR20250166224A - 세포막 단백질을 검출하는 방법 - Google Patents

세포막 단백질을 검출하는 방법

Info

Publication number
KR20250166224A
KR20250166224A KR1020257034502A KR20257034502A KR20250166224A KR 20250166224 A KR20250166224 A KR 20250166224A KR 1020257034502 A KR1020257034502 A KR 1020257034502A KR 20257034502 A KR20257034502 A KR 20257034502A KR 20250166224 A KR20250166224 A KR 20250166224A
Authority
KR
South Korea
Prior art keywords
cell membrane
embedding medium
antibody
fixed tissue
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257034502A
Other languages
English (en)
Korean (ko)
Inventor
타카요시 이도
후미요시 오카노
Original Assignee
도레이 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도레이 카부시키가이샤 filed Critical 도레이 카부시키가이샤
Publication of KR20250166224A publication Critical patent/KR20250166224A/ko
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57484—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/36—Embedding or analogous mounting of samples
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020257034502A 2023-03-28 2024-03-27 세포막 단백질을 검출하는 방법 Pending KR20250166224A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2023-050776 2023-03-28
JP2023050776 2023-03-28
PCT/JP2024/012221 WO2024204325A1 (ja) 2023-03-28 2024-03-27 細胞膜タンパク質を検出する方法

Publications (1)

Publication Number Publication Date
KR20250166224A true KR20250166224A (ko) 2025-11-27

Family

ID=92906670

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257034502A Pending KR20250166224A (ko) 2023-03-28 2024-03-27 세포막 단백질을 검출하는 방법

Country Status (7)

Country Link
EP (1) EP4692791A1 (https=)
JP (1) JPWO2024204325A1 (https=)
KR (1) KR20250166224A (https=)
CN (1) CN120677381A (https=)
AU (1) AU2024242849A1 (https=)
MX (1) MX2025010250A (https=)
WO (1) WO2024204325A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077057A1 (en) 2003-02-27 2004-09-10 Dakocytomation Denmark A/S Standard for immunohistochemistry, immunocytochemistry and molecular cytogenetics
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
WO2010016526A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
WO2011025442A1 (en) 2009-08-26 2011-03-03 General Electric Company Method and apparatus for antigen retrieval process

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252025A1 (en) * 2004-12-30 2006-11-09 Ventana Medical Systems, Inc. Low temperature deparaffinization
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び／又は予防用医薬組成物
PL2876447T3 (pl) * 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109890417A (zh) 2016-10-28 2019-06-14 东丽株式会社 癌的治疗和/或预防用药物组合物
AU2019242520B2 (en) 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US20220073641A1 (en) * 2018-12-28 2022-03-10 The University Of Tokyo Fusion protein of antibody that recognizes cancer cells and mutant streptavidin
JP2023050776A (ja) 2021-09-30 2023-04-11 パナソニックＩｐマネジメント株式会社 パネル装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004077057A1 (en) 2003-02-27 2004-09-10 Dakocytomation Denmark A/S Standard for immunohistochemistry, immunocytochemistry and molecular cytogenetics
WO2010016527A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の検出方法
WO2010016526A1 (ja) 2008-08-05 2010-02-11 東レ株式会社 癌の治療及び予防用医薬組成物
WO2011025442A1 (en) 2009-08-26 2011-03-03 General Electric Company Method and apparatus for antigen retrieval process

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lancet Oncol 2016; 17: e256-62
Pharm Res. 2015 Nov; 32(11): 3526-40

Also Published As

Publication number Publication date
CN120677381A (zh) 2025-09-19
EP4692791A1 (en) 2026-02-11
AU2024242849A1 (en) 2025-09-25
JPWO2024204325A1 (https=) 2024-10-03
WO2024204325A1 (ja) 2024-10-03
MX2025010250A (es) 2025-10-01

Similar Documents

Publication Publication Date Title
CN106415269B (zh) 直接免疫组织化学测定
KR101976219B1 (ko) 유방암의 바이오마커
Tátrai et al. Agrin, a novel basement membrane component in human and rat liver, accumulates in cirrhosis and hepatocellular carcinoma
JP5301630B2 (ja) 結腸直腸癌のためのマーカーとしてのタンパク質ｓａｔｂ２の使用
CN110337588A (zh) 用于定量免疫组织化学的方法和系统
JP5767116B2 (ja) 白金に基づく治療に対する応答の予測
AU2007291077B2 (en) Antibodies to an epitope of AGR2. assays and hybridomas
US9297812B2 (en) Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E
JP7011600B2 (ja) 被験体の免疫状態をモニタリングするための改善された方法
EP2615110A1 (en) Biomarker for diagnosing cancer and method of isolating cancer cell using the same
WO2012109233A2 (en) Methods for predicting recurrence risk in breast cancer patients
JP2012501440A (ja) 内分泌処置予測因子としてのａｎｌｎタンパク質
US20210048432A1 (en) Direct immunohistochemistry and immunocytochemistry methods
WO2010066252A1 (en) Method for evaluating pre-treatment
KR20250166224A (ko) 세포막 단백질을 검출하는 방법
US20120040361A1 (en) Methods and compositions for detection of lethal system and uses thereof
CA3285382A1 (en) Method for detecting cell membrane protein
KR20230151916A (ko) 항-igsf1 항체에 대한 암 환자의 감수성 예측용 바이오마커 조성물 및 이를 이용하는 방법
KR101140646B1 (ko) ＨＢｘ 형질전환 마우스 유래의 단백질 마커에 특이적인 항체를 포함하는 간암 진단 및 스크리닝용 키트 및 이를 이용한 간암 진단 및 스크리닝 방법
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
KR101567053B1 (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
US20250321232A1 (en) Chromogenic multiplexing methods and systems for identifying a cancer of unknown primary origin
US20140113385A1 (en) Compositions and Methods for Identifying Single Antigens or Other Molecules in Cell Preparations
US20190302124A1 (en) Compositions and Methods for Identifying Subjects Who May Benefit From Treatment With Therapeutic Agents
Kim et al. Immunohistochemical Analysis of mTOR Activity in Tissues

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000